Small-to-mid-sized pharmaceutical companies are an important customer base for suppliers, CDMOs, and CMOs. Learn about key trends and first-hand experience from pharmaceutical companies on key issues impacting the customer–supplier relationship. For speakers and topics, click on the session details below.
C-suite, senior, and mid-level executives from contract service providers and suppliers of products and services used in chemical, pharmaceutical, and biopharmaceutical development and manufacturing, packaging, and the related supply chain. Key job functions of attendees include: Business Development, Sales, Marketing, Project Management, Development, and Manufacturing.
Please note: To deliver targeted insight and create a comfortable environment for attendees, DCAT and its planning committees respectfully require that Suppliers’ Track attendees only be from contract service providers and suppliers. DCAT reserves the right to reassign registrants to the appropriate track.
Speaker: Brian Doyle, Managing Director and Partner, William Blair & Company
Speaker: Rick Panicucci, Senior Vice President, Chemistry, Manufacturing and Controls (CMC), QED Therapeutics
Speaker: Simon McGurk, Executive Director, Drug Product Development and Analytical Development, TESARO, Inc.
Featuring co-presentations of pharmaceutical companies and suppliers, this session offers candid perspectives on real-world challenges that arise in a campaign and how partners resolved those issues, including:
Cost-Competitive Manufacturing through Collaboration and Relationship Management
Merck’s antibiotic portfolio requires compliant, cost-competitive manufacturing of beta-lactam intermediates that are hard to source due to stringent segregation requirements. Merck looked early on, beyond loss of exclusivity, to create a cost-competitive manufacturing center of excellence that also provided regulatory, quality, and environmental, health, and safety (EHS) compliance. Merck and Asymchem will look back and share the details of this journey, from reconfiguring a CMO site into a beta-lactam facility and the initial challenges to the evolution of collaboration and relationship management that expanded this initial opportunity into a future collaboration.
Partnering for Security of Supply
The success of a business’s global supply chain depends on managing and mitigating risks and working with partners to achieve security of supply. Teva Pharmaceuticals and Amcor will provide lessons learned on how they resolved a potential disruption in supply of packaging materials using an advanced sourcing approach with upstream suppliers. They will discuss how they addressed short-and longer-term supply needs, enabled qualification of alternative product choices, and managed inventory and cost.
Sustainable Supply Chains and Manufacturing Cost Efficiency
Large-volume pharmaceuticals present supply-chain and manufacturing challenges in both development and commercialization. This co-presentation will provide a case study relating to the commercialization of high-volume therapeutics such as antimicrobials for the treatment of hepatitis C viral infection and bacteria that have become resistant to conventional antibiotics. Key insights are approaches used to evaluate the sustainability of a pharmaceutical supply chain with an emphasis on manufacturing cost. The presentation will further examine a process throughput concept based on (1) materials yield, (2) volumetric efficiency and (3) manufacturing time to bring about cost efficiencies.
In an era when chief procurement officers (CPOs) are trying to unlock the next gear of productivity, how can Big Data capabilities be used to transform procurement and sourcing practices? Gain first-hand insight from a CPO with experience gained from Fortune 500 companies Biogen, Kraft, and Kellogg’s on how Big Data tools and a new methodology, “constraintless bidding,” can be used to drive savings and value. Learn how a robust Big Data analytics strategy is a gateway to transition “analog” procurement practices into “digital” practices by enabling the application of robotic process automation (RPA), machine learning, natural language processing, and artificial intelligence.
Speaker: Wendell P. Weeks, Chairman and CEO, Corning Incorporated
What does it take to bring supplier-enabled innovation to fruition? Learn of the key success factors to build truly collaborative partnerships and to execute a winning strategy.
Wendell P. Weeks, Chairman and Chief Executive Officer (CEO) of Corning Incorporated, will share his insights and lessons learned from his 35-year career with Corning with examples from the company’s work with partners such as Apple Inc., Samsung Electronics Co., Ford Motor Company, Verizon, Sharp Corporation and most recently, Pfizer, Inc. and Merck & Co., Inc.
In 2017, Corning announced a planned investment of $4 billion with the introduction of a new product, Corning Valor Glass, for parenteral drug packaging that was the outgrowth of its partnership with Merck & Co., Inc. and Pfizer, Inc., which provided insights on pharmaceutical formulation and manufacturing processes.
As a result of the companies’ common goal to improve glass quality and promising results from initial testing, Corning is making an initial investment of $500 million as the first part of planned investment of $4 billion. Mr. Weeks will discuss the structure and governance of the collaboration and how the companies partnered in new product development, including addressing ways to lower systems costs and improve manufacturing efficiency, in order to bring the product to market.
Click here for full bio.
Simon McGurk, PhD
Executive Director, Drug Product Development and Analytical Development
Simon McGurk, PhD, is Executive Director of Drug Product Development and Analytical Development at TESARO, Inc., a Waltham, Massachusetts-based biopharmaceutical company. In this role, he is responsible for the development and validation of TESARO’s pipeline of small- and large-molecule drug products using a global network of contract development and manufacturing organizations. During his 19 years in the pharmaceutical industry, he has been involved in the approval of over 16 drug products in the areas of oncology, cardiovascular, pain management, immunotherapies, and antibacterial therapies.
Dr. McGurk earned his undergraduate degree from the School of Engineering at the University of Liverpool, UK and his PhD from the School of Pharmacy at the University of Nottingham, UK.
Managing Director and Partner
William Blair & Company
Brian Doyle is Managing Director and a Partner at William Blair & Company, where he leads its pharmaceutical services investment-banking practice. Prior to joining William Blair & Company in 2000, he spent three years at Abbott Laboratories working in a variety of finance and accounting positions and worked for four years at Price Waterhouse LLP in the audit and financial consulting practice focused primarily on middle-market companies. He has a bachelor’s of science in accounting from Villanova and an MBA from the Harvard Business School. He also is a certified public accountant.
James Gage, PhD
Chief Scientific Officer
James Gage, PhD, is the Head of Research and Development and Chief Scientific Officer for Asymchem, where he manages implementation of commercial processes in Asymchem’s manufacturing facilities and leads efforts to expand the company’s capabilities through development and application of new technology.
He has 27 years of experience in process chemistry and other aspects of pharmaceutical chemistry, manufacturing and controls (CMC). Prior to joining Asymchem in early 2006, Dr. Gage worked for Pfizer and Upjohn for over 14 years. He earned a PhD in chemistry with Professor David Evans at Harvard University.
Chief Procurement Officer
Walter Charles is the Chief Procurement Officer (CPO) at Biogen, where his global procurement teams support the purchase of billions of dollars a year of products and services supporting research & development, manufacturing, marketing, legal, capital, information technology, plant operations, travel, and general and administrative services. Prior to joining Biogen, he held CPO roles at companies such as Kraft Foods, Kellogg’s, Johnson & Johnson Consumer Supply Chain, and Cordis (one of Johnson & Johnson’s former medical devices companies). As such, he has the unique perspective of serving on supply-chain leadership teams and leading procurement transformations across multiple industries, including biotechnology, consumer packaged goods, pharmaceutical, and medical devices.
Executive Director of Project Management
STA Pharmaceutical, a WuXi AppTec company
Tangqing Li is Executive Director of Project Management, STA Pharmaceutical, a WuXi AppTec company, where he heads US-based project management. He has extensive knowledge and experience in both early- and late-phase drug development, including process validations, program management, and regulatory filings. He earned his PhD in organic chemistry at Rice University and his bachelor’s of science in chemistry at Peking University.
Prashant S. Savle, PhD
Director, Commercialization Projects, Global Procurement
Merck & Co., Inc.
Prashant S. Savle, PhD, is Director, Commercialization Projects, Global Procurement, Merck & Co., Inc., where his responsibilities include commercialization of drug substances and non-sterile and sterile drug-product formulations.
He has over 20 years of technical, business, and program-management experience, including global experience in technology development and scale-up, research and development, and clinical active pharmaceutical ingredient, sourcing, process validation, and commercial contract management. He brings a unique blend of experience from buyer-side sourcing and as a project manager with large contract manufacturing organizations, such as Rhodia ChiRex, Avecia Biotechnology, Inc. and Sigma-Aldrich Fine Chemicals.
Dr. Savle has supported drug-substance manufacturing projects spanning small molecules, antibiotics, bioconjugates, peptides, and oligonucleotides and has been a part of launch teams that have obtained 20 new drug approvals to date. He has a PhD in organic chemistry from the University of Cambridge, UK.
Register for Suppliers' Track Download Event Brochure
The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.